GlaxoSmithKline PLC Director/PDMR Shareholding (6312J)
14 Abril 2020 - 10:31AM
UK Regulatory
TIDMGSK
RNS Number : 6312J
GlaxoSmithKline PLC
14 April 2020
GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Ms E Walmsley
=== ============================ =================================================
b) Position/status Chief Executive Officer
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 8 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 8 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP 15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Mr R Connor
=== ============================ =================================================
b) Position/status President, Global Vaccines
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 8 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 8 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP 15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Ms D Conrad
=== ============================ =================================================
b) Position/status SVP, Human Resources
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 8 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 8 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Mr N Hirons
=== ============================ =================================================
b) Position/status SVP, Global Ethics and Compliance
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 8 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 8 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Ms S Jackson
=== ============================ =================================================
b) Position/status SVP, Global Communications and CEO Office
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 8 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 8 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===================================================================================
a) Name Mr D Jackson
=== ============================ =====================================================
b) Position/status PCA of Ms S Jackson (SVP, Global Communications
and CEO Office)
=== ============================ =====================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===================================================================================
a) Name GlaxoSmithKline plc
=== ============================ =====================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =====================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============== =================================
GBP15.3562 8 (partnership shares)
=== ============================ ============== =================================
GBP15.3562 8 (matching shares)
============== =================================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP15.3562
=== ============================ =====================================================
e) Date of the transaction 2020-04-09
=== ============================ =====================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =====================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Mr D Redfern
=== ============================ =================================================
b) Position/status Chief Strategy Officer
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 8 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 8 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Mr R Simard
=== ============================ =================================================
b) Position/status President, Pharmaceuticals Supply Chain
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 9 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 9 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 18 Ordinary Shares
Price GBP15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Mr P Thomson
=== ============================ =================================================
b) Position/status President, Global Affairs
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 8 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 8 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Ms D Waterhouse
=== ============================ =================================================
b) Position/status Chief Executive Officer of ViiV Healthcare
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 8 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 8 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
1. Details of PDMR/person closely associated with them
('PCA')
=== ===============================================================================
a) Name Ms V Whyte
=== ============================ =================================================
b) Position/status Company Secretary
=== ============================ =================================================
c) Initial notification/ Initial notification
amendment
=== ============================ =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=== ===============================================================================
a) Name GlaxoSmithKline plc
=== ============================ =================================================
b) LEI 5493000HZTVUYLO1D793
=== ============================ =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
=== ===============================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
=== ============================ =================================================
b) Nature of the Acquisition of Ordinary Shares under the
transaction Company's Share Reward Plan.
=== ============================ =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
=== ============================ ============= ==============================
GBP15.3562 8 (partnership shares)
=== ============================ ============= ==============================
GBP15.3562 8 (matching shares)
============= ==============================
d) Aggregated information
===
Aggregated volume 16 Ordinary Shares
Price GBP15.3562
=== ============================ =================================================
e) Date of the transaction 2020-04-09
=== ============================ =================================================
f) Place of the London Stock Exchange (XLON)
transaction
=== ============================ =================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEZLFFBZLLBBV
(END) Dow Jones Newswires
April 14, 2020 11:31 ET (15:31 GMT)
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
